1767MO External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials
Year: 2023
Type: article
Source: Annals of Oncology
Authors: C.T.A. Parker, L. Mendes, E. Grist, V. Liu, D. Van der Wal, J.R. Griffin, E. Chen, P.T. Tran, D. Spratt, L.R. Murphy, A. Sachdeva, S. Lall, M.K. Parmar, M.R. Sydes, L.C. Brown, A. Esteva, F. Feng, N.W. Clarke, N.D. James, G. Attard
Institutions: University College London, Case Western Reserve University, MRC Clinical Trials Unit at UCL, University of Manchester, The Christie NHS Foundation Trust, University of California, San Francisco, University of California San Francisco Medical Center, Institute of Cancer Research, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4387810251